REG - Destiny Pharma PLC - 2024 Annual General Meeting and Statement

Destiny PharmaAnnouncement

12/06/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240612:nRSL0385Sa&default-theme=true

RNS Number : 0385S  Destiny Pharma PLC  12 June 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

2024 Annual General Meeting and Statement

Brighton, United Kingdom ‐ 12 June 2024 ‐ Destiny Pharma plc (AIM: DEST) a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life‐threatening infections, will today
hold its 2024 Annual General Meeting (AGM) at 11am BST.

Ahead of the formal proceedings of the Meeting, Sir Nigel Rudd, Chairman of
Destiny Pharma, will make the following statement:

"We continue to believe XF-73 Nasal has enormous market potential and can make
a huge difference in the prevention of surgical site infections, and the
reduction in the usage of antibiotics.

As announced in our Full Year Results, the Company and Board have been focused
on seeking support to advance the XF-73 Nasal programme through Phase 3
clinical trials. While licencing activities continue, given our current cash
runway, feedback from potential partners has led us to evaluate a range of
strategic options. Our review of these options has continued since the Full
Year Results and we intend to provide an update to the market in the coming
weeks."

Immediately following the conclusion of the AGM, Chris Tovey, Chief Executive
Officer of Destiny Pharma, will make a short corporate presentation that will
be followed by a Q&A session.

Shareholders that wish to attend the AGM remotely should register for the
event in advance by using the following link:
https://www.investormeetcompany.com/destiny‐pharma‐plc/register‐investor
(https://url.avanan.click/v2/___https:/www.investormeetcompany.com/destiny%E2%80%90pharma%E2%80%90plc/register%E2%80%90investor___.YXAxZTpzaG9yZWNhcDphOm86YTgzMGQ5Y2U3ZDY1NDZiNDliNTFiY2RjNDdjNGYzYzk6NjphNjJiOjlhM2M0MTBlMWUyMWM5MDA0ZmExOTMxZTk4ZmY1NmNhOTJkMTMwMGIwZmRjNTBlY2U3MjhlZmZmOGNhNzg3MTU6cDpU)

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

About XF-73 Nasal

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially
being developed for the prevention of post-surgical staphylococcal infections,
such as methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the hospital
setting. XF‑73 has been awarded both Qualified Infectious Disease Product
(QIDP) and Fast Track status by the US FDA.

 

Forward looking statements

Certain information contained in this announcement, including any information
as to the company's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the company's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the company operates. The Directors of the company believe that the
expectations reflected in these statements are reasonable but may be affected
by a number of variables which could cause actual results or trends to differ
materially. Each forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future or are beyond the
company's control. Forward looking statements are not guarantees of future
performance. Even if the company's actual results of operations, financial
condition and the development of the industries in which the company operates
are consistent with the forward-looking statements contained in this document,
those results or developments may not be indicative of results or developments
in subsequent periods.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMEAKKFFSALEFA